Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma

Oncology

Volumn 65, Issue 4, 2003, Pages 337-346

  Bendardaf, R ^a,b   Lamlum, H ^a,b   Vihinen, P ^a,b   Ristamaki R ^a   Laine, J ^a   Pyrhonen S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Apoptotic index; Colorectal carcinoma; MMP 1; MMP 13; MT1 MMP

Indexed keywords

COLLAGENASE 3; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; COLLAGENASES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MIDDLE AGED; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0346058325     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074647     Document Type: Article

References (67)

1. Coussens LM, Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895-904.
2. Kelly T, Yan Y, Osborne RL, Athota AB, Rozypal TL, Colclasure JC, et al: Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis 1998;16:501-512.
3. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
4. Vihinen P, Kahari VM: Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-166.
5. Kahari VM, Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:1:34-45.
6. Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995;14:908-917.
7. Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(suppl):S42-51.
8. Liotta LA, Saidel MG, Kleinerman J: The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976;36:889-894.
9. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68.
10. Seiki M: Membrane-type matrix metalloproteinases. APMIS 1999;107/1:137-143.
11. Imanishi Y, Fuji M, Tokumaru Y, Tomita T, Kanke M, Kanzaki J, et al: Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol 2003;31:895-904.
12. Benbow U, Schoenermark MP, Mitchell TI, Rutter JL, Shimokawa K, Nagase H, et al: A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type 1 collagen. J Biol Chem 1999;274:25371-2537.
13. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, et al: Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80:733-743.
14. Ito T, Iho M, Shiozawa J, Naito S, Kanematsu T, Sekine I: Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor. Mod Pathol 1999;12:669-674.
15. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-462.
16. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, et al: Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999;59:4225-4227.
17. Knauper V, Cowell S, Smith B, Lopez-Otin C, O'Shea M, Morris H, et al: The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997;272:7608-7616.
18. Pendas AM, Uria JA, Jimenez MG, Balbin M, Freije JP, Lopez-Otin C: An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in anti-tumor therapies. Clin Chim Acta 2000;291/2:137-155.
19. Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C: Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS 1999;107/1:45-53.
20. Tsukifuji R, Tagawa K, Hatamochi A, Shinkai H: Expression of matrix metalloproteinase-1, -2, and -3 in squamous cell carcinoma and actinic keratosis. Br J Cancer 1999;80:1087-1091.
21. Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U, et al: Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999;154:469-480.
22. Sarraf CE, Bowen ID: Proportions of mitotic and apoptotic cells in a range of untreated experimental tumours. Cell Tissue Kinet 1988;21/1:45-49.
23. Deschner E: Kinetics of Normal, Preneoplastic, and Neoplastic Colon Epithelium. San Diego, Academic Press, 1990.
24. Steel G: Growth Kinetics of Tumours. London, Oxford University Press, 1997.
25. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K: Apoptotis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994;30A:2068-2073.
26. Lipponen PK, Aaltomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994;173:333-339.
27. Leoncini L, Del VM, Megha T, Barbini P, Galieni P, Pileri S, et al: Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 1993;142:755-763.
28. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Toren JS, Tveit KM, et al: Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002;13:1868-1873.
29. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47/1:207-214.
30. Laine VJ, Nyman KM, Peuravuori HJ, Henriksen K, Parvinen M, Nevalainen TJ: Lipopolysaccharide induced apoptosis of rat pancreatic acinar cells. Gut 1996;38:747-752.
31. Billig H, Furuta I, Hsueh AJ: Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 1993;133:2204-2212.
32. Yamaguchi A, Kurosaka Y, Ishida T, Nishimura G, Kanno M, Kosaka T, et al: Clinical significance of tumor marker NCC-ST 439 in large bowel cancers. Dis Colon Rectum 1991;34: 921-924.
33. Inoue T, Yashiro M, Nishimura S, Maeda K, Sawada T, Ogawa Y, et al: Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 1999;4/1:73-77.
34. Grigioni WF, D'Errico A, Fortunato C, Fiorentino M, Mancini AM, Stetler-Stevenson WG, et al: Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol 1994;7/2:220-225.
35. Miyajima Y, Nakano R, Morimatsu M: Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995;104:678-684.
36. Westerlund A, Apaja-Sarkkinen M, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T: Gelatinase A-immunoreactive protein in ovarian lesions - Prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999;75/1:91-98.
37. Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W, et al: Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:3944-3948.
38. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G, et al: MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohisto-chemistry and mRNA in situ hybridization. Gynecol Oncol 1999;73:372-382.
39. Walther MM, Kleiner DE, Lubensky IA, Pozzatti R, Nyguen T, Gnarra JR, et al: Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology 1997;50/2:295-301.
40. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-1162.
41. Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G: Expression of tissue inhibitor of metalloproteinase TIMP-2 in human colorectal cancer - A predictor of tumour stage. Br J Cancer 1997;76:805-811.
42. Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, Cavrini G, et al: Relevance of biologic markers in colorectal carcinoma: A comparative study of a broad panel. Cancer 2002;94:647-657.
43. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20:1085-1091.
44. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, et al: Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379-2387.
45. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Garbisa S, et al: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: Clinical and prognostic implications. Anticancer Res 1995;15:2799-2804.
46. Yamashita K, Mori M, Shiraishi T, Shibuta K, Sugimachi K: Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6:1169-1174.
47. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001;19:1118-1127.
48. Zeng ZS, Shu WP, Cohen AM, Guillem JG: Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: Evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002;8/1:144-148.
49. van der Stappen JW, Hendriks T, Wobbes T: Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 1990;45:1071-1078.
50. Otani Y, Okazaki I, Arai M, Kameyama K, Wada N, Maruyama K, et al: Genetic expression of interstitial collagenase (matrix metallo-proteinase 1) in gastrointestinal tract cancers. J Gastroenterol 1994;29:391-397.
51. Bufill JA: Colorectal cancer: Evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779-788.
52. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, et al: Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol 2000;95:2953-2957.
53. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-1750.
54. Johansson N, Saarialho-Kere U, Airola K, Herva R, Nissinen L, Westermarck J, et al: Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. Dev Dyn 1997;208:387-397.
55. Stahle-Backdahl M, Sandstedt B, Bruce K, Lindahl A, Jimenez MG, Vega JA, et al: Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. Lab Invest 1997;76:717-728.
56. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM: Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997;151:499-508.
57. Watanabe I, Toyoda M, Okuda J, Tenjo T, Tanaka K, Yamamoto T, et al: Detection of apoptotic cells in human colorectal cancer by two different in situ methods: Antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J cancer Res 1999;90/2:188-193.
58. Evertsson S, Bartik Z, Zhang H, Jansson A, Sun XF: Apoptosis in relation to proliferating cell nuclear antigen and Dukes' stage in colorectal adenocarcinoma. Int J Oncol 1999;15/1:53-58.
59. Tatebe S, Ishida M, Kasagi N, Tsujitani S, Kaibara N, Ito H: Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: Analysis by terminal-deoxynucleotidyl-transferase- mediated dUTP-biotin nick end labeling. Int J Cancer 1996;65/2:173-177.
60. Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, Chadwick C, et al: Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995;37/1:1-9.
61. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, et al: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001;91/11:2026-2032.
62. Sugamura K, Makino M, Kaibara N: Apoptosis as a prognostic factor in colorectal carcinoma. Surg Today 1998;28/2:145-150.
63. Malhotra S, Newman E, Eisenberg D, Scholes J, Wieczorek R, Mignatti P, et al: Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: A possible mechanism of neoplastic progression. Dis Colon Rectum 2002;45:537-543.
64. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149/1:273-282.
65. Zeng ZS, Huang Y, Cohen AM, Guillem JG: Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. Clin Oncol 1996;14:3133-3140.
66. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, et al: Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 2002;86:1864-1870.
67. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.